Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · IEX Real-Time Price · USD
2.59
-0.11 (-4.07%)
Mar 30, 2023, 10:40 AM EDT - Market open
-4.07%
Market Cap 181.52M
Revenue (ttm) 1.50M
Net Income (ttm) -54.17M
Shares Out 70.49M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE 1.79
Dividend n/a
Ex-Dividend Date n/a
Volume 16,066
Open 2.70
Previous Close 2.70
Day's Range 2.53 - 2.74
52-Week Range 1.41 - 3.35
Beta 1.10
Analysts Buy
Price Target 4.85 (+87.26%)
Earnings Date May 8, 2023

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2017
Employees 44
Stock Exchange NASDAQ
Ticker Symbol OVID
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $4.85, which is an increase of 87.26% from the latest price.

Price Target
$4.85
(87.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

2 weeks ago - GlobeNewsWire

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

3 weeks ago - GlobeNewsWire

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

3 weeks ago - GlobeNewsWire

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

1 month ago - GlobeNewsWire

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

1 month ago - GlobeNewsWire

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Li...

3 months ago - GlobeNewsWire

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

4 months ago - GlobeNewsWire

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

5 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

6 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

7 months ago - GlobeNewsWire

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

8 months ago - GlobeNewsWire

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

10 months ago - GlobeNewsWire

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve ...

11 months ago - GlobeNewsWire

3 Biotech Stocks Under $10 to Add to Your Buy List

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on ...

Other symbols: ABCLSIGA
1 year ago - InvestorPlace

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

1 year ago - GlobeNewsWire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

1 year ago - GlobeNewsWire

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epileps...

1 year ago - GlobeNewsWire

Healx and Ovid Therapeutics to Enter Strategic Partnership

– Ovid to License Gaboxadol to Healx –

1 year ago - GlobeNewsWire

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact

Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, inc...

Other symbols: AZN
1 year ago - Benzinga

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

1 year ago - GlobeNewsWire

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

1 year ago - GlobeNewsWire

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

1 year ago - GlobeNewsWire

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological d...

1 year ago - GlobeNewsWire

A Trio of Magic Formula Stock Picks

In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.

Other symbols: DBDVNT
1 year ago - GuruFocus

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors

1 year ago - GlobeNewsWire